Pacifico Biolabs, a German foodtech company developing protein ingredients through mycelium fermentation, has closed a €7 million Series A funding round. The capital injection comes from a syndicate of five investors: Stray Dog Capital, TGFS, Sprout & About Ventures, Simon Capital, and FoodLabs.
The funding will support three primary strategic objectives: scaling production capacity, expanding the company’s team, and accelerating commercial product launches. These priorities reflect Pacifico Biolabs’ ambition to move from development into market deployment across multiple food and beverage applications.
Leveraging Existing Infrastructure
Pacifico Biolabs distinguishes itself through its use of mycelium fermentation technology combined with an innovative cost-reduction approach. Rather than constructing purpose-built facilities from scratch, the company leverages existing brewery infrastructure to produce its protein ingredients. This strategy significantly reduces capital expenditure while enabling faster deployment to market.
The approach taps into the established network of brewing facilities across Europe, many of which have underutilized fermentation capacity. By adapting these spaces for protein production, Pacifico Biolabs can achieve economies of scale without the substantial investment typically required for biotechnology manufacturing.
Expanding the Protein Alternative Market
The investment arrives as alternative protein production methods continue attracting capital and commercial interest across Europe. Mycelium-based proteins represent one of several emerging technologies competing to meet growing demand for sustainable, scalable protein sources that can serve food manufacturers and beverage companies seeking to reduce reliance on conventional animal agriculture.
Pacifico Biolabs’ approach targets the ingredient market, positioning its products as inputs for food and beverage manufacturers rather than direct-to-consumer offerings. This business model addresses a critical gap in the value chain where existing supply solutions face constraints around cost, sustainability, or availability.
Building European Foodtech Momentum
The funding round underscores continued investor confidence in European foodtech innovation. Germany has emerged as a particular hub for alternative protein development, with multiple companies pursuing different technological pathways including fermentation, precision fermentation, and plant-based processing.
The participation of established foodtech investors like FoodLabs alongside diversified venture capital firms suggests broad recognition of mycelium fermentation’s commercial potential. This mixed investor base typically indicates confidence that the company has progressed beyond early-stage validation toward demonstrable market readiness.
As Europe’s regulatory environment for novel food ingredients matures and consumer acceptance of alternative proteins strengthens, companies positioned to supply the manufacturing sector with scalable, cost-competitive ingredients occupy a strategic position within the broader protein transition movement.